Surgery Partners (SGRY)
(Delayed Data from NSDQ)
$27.28 USD
+0.53 (1.98%)
Updated May 30, 2024 04:00 PM ET
After-Market: $27.33 +0.05 (0.18%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth B Momentum A VGM
Price, Consensus and EPS Surprise
SGRY 27.28 +0.53(1.98%)
Will SGRY be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for SGRY based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SGRY
Surgery Partners (SGRY) Q1 Earnings and Revenues Beat Estimates
DocGo Inc. (DCGO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
SGRY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Earnings Preview: Surgery Partners (SGRY) Q1 Earnings Expected to Decline
SGRY vs. DOCS: Which Stock Should Value Investors Buy Now?
Surgery Partners (SGRY) Upgraded to Buy: What Does It Mean for the Stock?
Other News for SGRY
Unveiling Surgery Partners (SGRY)'s Value: Is It Really Priced Right? A Comprehensive Guide
July 19th Options Now Available For Surgery Partners (SGRY)
Surgery Partners’ Growth Prospects Bolster Buy Rating
Surgery Partners (SGRY) Outperforms with Strong Q1 and Strategic Focus: A Buy Rating Maintained
Surgery Partners price target lowered by $6 at Leerink, here's why